{
  "2024": [
    {
      "title": "Casgevy CRISPR therapy launches in US and UK",
      "description": "Vertex and CRISPR Therapeutics launched the world’s first approved CRISPR therapy—Casgevy—for sickle cell and beta-thalassemia.",
      "url": "https://www.crisprtx.com/",
      "morelink": "CRISPR Therapeutics"
    },
    {
      "title": "Generative AI in bioinformatics surges",
      "description": "2024 saw GenAI tools used for protein design, genomic diagnostics, and disease modeling, with open models like ESMFold and RoseTTAFold2 gaining traction.",
      "url": "https://ai.facebook.com/research/publications/esmf/",
      "morelink": "Meta AI"
    },
    {
      "title": "Biotech IPOs rebound to $8.52B",
      "description": "After 2022–23 stagnation, biotech IPOs rose by 68.4% to $8.52 billion globally, driven by oncology and rare disease startups.",
      "url": "https://www.biopharmadive.com/news/biotech-ipo-market-outlook-2024/652831/",
      "morelink": "BioPharma Dive"
    },
    {
      "title": "AI in clinical trials grows",
      "description": "AI-driven patient selection, trial simulation, and real-time analysis became widely adopted by CROs and pharma companies.",
      "url": "https://www.nature.com/articles/s41587-024-00032-x",
      "morelink": "Nature Biotech"
    },
    {
      "title": "Bioprinting used in regenerative therapies",
      "description": "3D bioprinting progressed from prototyping to clinical trial stages, including cartilage repair and drug screening via organoids.",
      "url": "https://www.genengnews.com/news/3d-bioprinting-reaches-clinic/",
      "morelink": "GEN"
    }
  ]
}
